1
|
Casas G, Limeres J, Gutierrez-Garcia L, La Mura L, Guala A, Teixido G, Escalona R, Gonzalez-Del-Hoyo M, Gimeno JR, Zorio E, Garcia-Pavia P, Barriales R, Evangelista A, Ferreira-Gonzalez I, Rodriguez-Palomares JF. Prognosis of left ventricular noncompaction with preserved ejection fraction. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Left ventricular noncompaction (LVNC) is a poorly defined entity with heterogeneous prognosis. LV ejection fraction (LVEF) is one of the main predictors of major adverse cardiovascular events (MACE). However, outcomes of LVNC patients with preserved LVEF (pEF) remain uncertain.
Purpose
The aim of our study was to determine the incidence and predictors of MACE in LVNC patients with pEF as well as to assess the evolution of LVEF throughout follow-up.
Methods
We conducted a retrospective, longitudinal, multicentre cohort study. Consecutive patients with transthoracic echocardiography (TTE) and/or cardiac magnetic resonance (CMR) diagnostic criteria for LVNC and initially pEF (LVEF≥50%) were recruited. MACE were defined as a composite of heart failure (HF), ventricular arrhythmias (VA), systemic embolisms (SE) and/or all-cause mortality. Progressive systolic dysfunction was defined as an LVEF<50% at last TTE and/or an absolute ≥10-point decrease in LVEF from first to last TTE. Lower limit of LVEF values were considered 50–53% for TTE and 50–57% for CMR, according to current recommendations.
Results
A total of 305 patients from 12 centres were included from 2000 to 2018. Age was 38±19 years, 165 (54%) were men and 185 (61%) were probands. LVEF was 62±8% and 8% had late gadolinium enhancement (LGE). During a median follow-up of 4.7 (IQR 2.1–7.4) years, MACE occurred in 40 (13%) patients with an incidence rate of 2.96 (95% CI 2.17–4.04) events per 100 person-years: 8 HF, 27 VA, 3 SE and 5 deaths. LVEF by TTE (HR 0.95, 95% CI 0.90–0.99, p=0.035) and age (HR 1.02, 95% CI 1.01–1-04, p=0.04) were the only variables independently associated with the endpoint. Patients with lower limit LVEF values showed an increased risk of MACE (Figure 1). Among probands, those with family aggregation presented a higher incidence of MACE compared to nonfamilial cases (HR 2.74, p=0.043). A positive genotype was not associated.
Sixty-one (21%) patients experienced progressive systolic dysfunction: 31 (11%) had an LVEF<50% and 48 (17%) an absolute ≥10-point decrease in LVEF at last follow-up. On multivariate analysis, LVEF by CMR was the only independent predictor (HR 0.96, 95% CI 0.92–0.99, p=0.031). Patients with lower limit LVEF values had an increased risk (Figure 2). In this subgroup, LGE was also associated with the endpoint (HR 3.52, p=0.011). Family aggregation was not associated, while a positive genotype correlated with lower risk (HR 0.52, p=0.029).
Conclusions
Patients with left ventricular noncompaction and preserved ejection fraction carry a moderate risk of major adverse cardiovascular events and progressive systolic dysfunction. LVEF remains the main predictor of outcomes in this subgroup. Patients with lower limit LVEF values are at increased risk, probably suggesting subclinical systolic dysfunction. Therefore, they should be carefully monitored.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- G Casas
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - J Limeres
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | - L La Mura
- Federico II University Hospital, Naples, Italy
| | - A Guala
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - G Teixido
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - R Escalona
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | - J R Gimeno
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - E Zorio
- Hospital Universitario y Politecnico La Fe, Valencia, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - R Barriales
- University Hospital Complex A Coruña, A Coruña, Spain
| | - A Evangelista
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | | |
Collapse
|
2
|
Rodenas Alesina E, Rodriguez-Palomares J, Oller-Bach M, Jordan P, Badia C, Herrador L, Garcia-De-Acilu M, Clau-Terre F, Gonzalez-Del-Hoyo M, Fernandez-Galera R, Servato L, Casas G, Baneras J, Ferreira-Gonzalez I. Routine advanced echocardiography in the evaluation of cardiovascular sequelae of COVID19 survivors with elevated cardiovascular biomarkers. Eur Heart J 2021. [PMCID: PMC8767606 DOI: 10.1093/eurheartj/ehab724.1594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Background COVID19 has been related to elevated CVB and biventricular dysfunction during hospitalization. However, it is unknown whether patients with biomarker elevation exhibit long-lasting abnormalities in cardiac function. Purpose To determine, using advanced echocardiography, the prevalence and type of cardiovascular sequelae after COVID19 infection with marked elevation of cardiovascular biomarkers (CVB), and their prognostic implications. Methods All patients admitted from March 1st to May 25th, 2020 to a tertiary referral hospital were included. Patients with cardiovascular disease antecedent, death during admission, or the first 30 days after discharge were excluded. Patients with hs-TnI >45 ng/L, NT-proBNP >300 pg/ml, and D-dimer >8000 ng/ml were separated based on each CVB elevation and matched with COVID controls (three biomarkers within the normal range) based on intensive care requirements and age. Results From a total of 2025 hospitalized COVID19 patients, 80 patients with significantly elevated CVB and 29 controls were finally included. No differences in baseline characteristics were observed among groups, but elevated CVB patients were sicker. Follow-up echocardiograms showed no differences among groups regarding LVEF or RV diameters, but TAPSE was lower if hs-TnI or D-dimer were elevated. Hs-TnI patients also had lower global myocardial work and global longitudinal strain. The presence of an abnormal echocardiogram was more frequent in the elevated CVB group compared to controls (23.8 vs 10.3%, P=0.123) but mainly associated with mild abnormalities in deformation parameters. Management did not change in any case and no major cardiovascular events except deep vein thrombosis occurred after a median follow-up of 7 months (Figure 1). Conclusions Minimal abnormalities in cardiac structure and function are observed in COVID19 survivors without previous cardiovascular diseases who presented a significant CVB rise at admission, with no impact on patient management or short-term prognosis. These results do not support a routine screening program after discharge in this population. Funding Acknowledgement Type of funding sources: None.
Figure 1 ![]()
Collapse
Affiliation(s)
| | | | - M Oller-Bach
- University Hospital Vall d'Hebron, Barcelona, Spain
| | - P Jordan
- University Hospital Vall d'Hebron, Barcelona, Spain
| | - C Badia
- University Hospital Vall d'Hebron, Barcelona, Spain
| | - L Herrador
- University Hospital Vall d'Hebron, Barcelona, Spain
| | | | - F Clau-Terre
- University Hospital Vall d'Hebron, Barcelona, Spain
| | | | | | - L Servato
- University Hospital Vall d'Hebron, Barcelona, Spain
| | - G Casas
- University Hospital Vall d'Hebron, Barcelona, Spain
| | - J Baneras
- University Hospital Vall d'Hebron, Barcelona, Spain
| | | |
Collapse
|